CERo Therapeutics Holdings, Inc.

OTC: CERO · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001870404Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 11DQ —GM —SS 23

v0.1 · 35/100 weight · pillars only

↑ market scale, workforce scale · ↓ Piotroski F, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$19.9M

Employees

as of 2026-08-29

Market cap

$496.2k

as of 2026-08-29

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$19.9M-$19.9M2025

Operating income-$15.3M-$15.3M2024

Total assets$3.6M$3.6M2025

Liabilities$9.1M$9.1M2025

Equity-$5.4M-$5.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is CERo Therapeutics Holdings, Inc.’s financial profile?

CERo Therapeutics Holdings, Inc. earned -$19.9M in FY2025 net income.

Peers · Healthcare

Parallel Industries Inc.——Itoco Inc.——Regenicin, Inc.——Virpax Pharmaceuticals, Inc.——Binovi Technologies Corp.——Emerging World Pharma, Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$053D

Key facts

CEOChristopher Ehrlich

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeOTC: CERO

Employees8

IPO date2021-11-30

Latest filings

10-Q2026-08-14 8-K2026-07-17 8-K2026-06-26 8-K2026-05-29 10-Q2026-05-15 8-K2026-05-01 10-K2026-04-15 8-K2026-04-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.